| Objective: To observe the clinical effect of aripiprazole combine with non-convulsive electroshock (MECT) for children and adolescents with first episode schizophrenia. Methods: 94 children and adolescents with first episode schizophrenia who were admitted to Yiling Kangning Psychiatric Hospital from August 2022 to August 2024 were divided into control group (received aripiprazole, n=47) and study group (received aripiprazole combined with MECT, n=47) by using random number table method.The clinical efficacy, dysfunction scale [Positive and Negative Symptom Scale (PANSS), Montreal Cognitive Assessment Scale (MoCA), Wechsler Memory Scale (WMS)], glucose and lipid metabolism indexes [low density lipoprotein cholesterol (LDL-C), glycated hemoglobin (HbAlc), total cholesterol (TC), fasting blood glucose (FBG), High density lipoprotein cholesterol (HDL-C), inflammatory factor indexes [interleukin-1β (IL-1β), tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6)], neurocytokine levels [serum brain-derived neurotrophic factor (BDNF), s100β protein (s100β), homocysteine (Hcy)] and the occurrence of adverse reactions were compared between the two groups. Results: Compared with the control group after treatment, the clinical total effective rate, MoCA, WMS score, HDL-C, BDNF were higher, PANSS score, HbAlc, FBG, TC, LDL-C, TNF-α, IL-1β, IL-6, s100β and Hcy were lower in the study group (P<0.05). There was no difference in the incidence of adverse reactions between the two groups (P>0.05). Conclusion: Aripiprazole combine with MECT in the treatment of in children and adolescents with first episode schizophrenia can reduce the degree of inflammation, regulate glucose and lipid metabolism, improve clinical symptoms and neurological function of children, with good safety. |
